1-bromo-3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-nitrobenzene | 936844-08-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-nitrobenzene
• 英文别名: 1-(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)-3-bromo-5-nitrobenzene；1-bromo-3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-5-nitrobenzene
• CAS: 936844-08-5
• 化学式: C₁₃H₁₈BrNO₆
• 分子量: 364.193
• InChiKey: YGAMLSLTDMFMJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  82.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-bromo-3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-nitrobenzene 在 吡啶 、 tin(ll) chloride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 6.0h， 生成 N-(3-bromo-5-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}phenyl)-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  Covalent Assembly of Molecular Ladders

  摘要：

  [n]-Rung molecular ladders (n = 3-6) have been prepared by reacting discrete, complimentary m-phenylene ethynylene oligomers using imine formation/exchange. The nanostructures, which in the largest case measure approximately 1.6 x 6.2 nm, have been characterized by MALDI mass spectrometry and gel permeation chromatography. Although the ladder structure is a significant component in each case, the formation of higher molecular weight byproducts becomes more pronounced as the length increases. These structures represent an important first step toward the synthesis of larger, more sophisticated two-dimensional molecular grids.

  DOI：

  10.1021/ja0690013
• 作为产物：
  描述：

  三甘醇单甲醚 、 3,5-二硝基溴苯 在 氢氧化钾 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以83%的产率得到1-bromo-3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-nitrobenzene
  参考文献：
  名称：

  Covalent Assembly of Molecular Ladders

  摘要：

  [n]-Rung molecular ladders (n = 3-6) have been prepared by reacting discrete, complimentary m-phenylene ethynylene oligomers using imine formation/exchange. The nanostructures, which in the largest case measure approximately 1.6 x 6.2 nm, have been characterized by MALDI mass spectrometry and gel permeation chromatography. Although the ladder structure is a significant component in each case, the formation of higher molecular weight byproducts becomes more pronounced as the length increases. These structures represent an important first step toward the synthesis of larger, more sophisticated two-dimensional molecular grids.

  DOI：

  10.1021/ja0690013

文献信息

• KINASE INHIBITORS
  申请人：Topivert Pharma Limited

  公开号：US20140296208A1

  公开（公告）日：2014-10-02

  There are provided compounds of formula I, wherein R 1A to R 1E , R 2 to R 5 , L and X 1 to X 3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了具有式I的化合物， 其中R 1A至R 1E，R 2至R 5，L和X 1至X 3在描述中给出了含义，这些化合物具有抗炎活性（例如通过抑制p38丝裂原活化蛋白激酶酶家族中的一个或多个成员；Syk激酶；和酪氨酸激酶Src家族的成员之一）并且在治疗中有用，包括在药物组合中，特别是在治疗炎症性疾病，包括肺部、眼睛和肠道的炎症性疾病。
• [EN] UREA DERIVATIVES USEFUL AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'URÉE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：RESPIVERT LTD

  公开号：WO2014162126A1

  公开（公告）日：2014-10-09

  There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了化学式I的化合物，其中R1A至R1E，R2至R5，L和X1至X3的含义如描述中所示，这些化合物具有抗炎活性（例如通过抑制p38丝裂原活化蛋白激酶酶家族中的一个或多个成员；Syk激酶；和酪氨酸激酶Src家族的成员之一）并且在治疗中有用，包括在药物组合中，特别是用于治疗炎症性疾病，包括肺部、眼睛和肠道的炎症性疾病。
• [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE
  申请人：RESPIVERT LTD

  公开号：WO2014076484A1

  公开（公告）日：2014-05-22

  There are provided compounds of formula I, (I) wherein R1 to R5, Ar and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了化合物I的化合物，化合物I的化合物中R1至R5，Ar以及X1至X3具有描述中给定的含义，这些化合物具有抗炎活性（例如通过抑制p38丝裂原活化蛋白激酶酶家族中的一个或多个成员；Syk激酶；以及酪氨酸激酶Src家族的成员之一）并且在治疗中有用，包括在药物组合中，特别是用于治疗炎症性疾病，包括肺部、眼睛和肠道的炎症性疾病。
• Kinase inhibitors
  申请人：Topivert Pharma Limited

  公开号：US10435361B2

  公开（公告）日：2019-10-08

  There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了式 I 的化合物、 其中 R1A 至 R1E、R2 至 R5、L 和 X1 至 X3 具有描述中给出的含义，这些化合物具有抗炎活性（例如通过抑制以下成员中的一种或多种：p38 丝裂原活化蛋白激酶家族；Syk 激酶；以及酪氨酸激酶 Src 家族成员），并可用于治疗，包括药物组合，特别是用于治疗炎症性疾病，包括肺、眼和肠道的炎症性疾病。
• UREA DERIVATIVES USEFUL AS KINASE INHIBITORS
  申请人：Respivert Limited

  公开号：EP2981535A1

  公开（公告）日：2016-02-10